Using compression gloves to reduce nerve pain from taxane chemotherapy
Tight Surgical Gloves to Prevent Chemotherapy-induced Peripheral Neuropathy: A Randomized Controlled Trial to Evaluate the Efficacy of Compression Therapy in Patients With Taxane-based Chemotherapy for Breast and Urogenital Cancer
This study is testing whether wearing compression gloves can help reduce nerve pain for breast cancer and urogenital carcinoma patients receiving taxane chemotherapy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 114 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | St.Gallen University of Applied Sciences Academic / other |
| Drugs / interventions | Chemotherapy |
| Locations | 1 site (Zurich) |
| Trial ID | NCT06464536 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of wearing tight surgical gloves to alleviate chemotherapy-induced peripheral neuropathy (CIPN) in patients undergoing taxane-based treatments. It is a randomized controlled trial conducted at the Comprehensive Cancer Center Zurich, where participants will be assigned to either a compression glove group or a control group wearing non-compressing gloves. The primary goal is to determine if compression therapy can significantly reduce the incidence of moderate to severe CIPN during treatment cycles. The study will involve patients with breast cancer or urogenital carcinoma receiving specific taxane therapies.
Who should consider this trial
Good fit: Ideal candidates are adults with breast cancer or urogenital carcinoma who are starting their first treatment with taxanes.
Not a fit: Patients with a history of neuropathy or those receiving other neurotoxic treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life for patients undergoing taxane chemotherapy by reducing painful side effects.
How similar studies have performed: Previous studies have suggested that compression therapy may effectively reduce CIPN, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Mamma or Urogenital carcinoma * first treatment with Taxanes (nab-Paclitaxel, Paclitaxel, Docetaxel) * signed informed consent * sufficient proficiency in German or English Exclusion Criteria: * other therapy that could have caused peripheral neuropathy within the last 24 months (Taxane, Platin, Vincaalkaloids, etc.) * History of neuropathy such as Raynaud's phenomenon, fibromyalgia and diabetic polyneuropathy * Use of polyneuropathy medications including duloxetine; gabapentin/pregabalin; topical amitriptyline, ketamine, baclofen; oral cannabinoids; tricyclic antidepressants; and ganglioside monosialic acid * such impaired cognition that prevents participation in the study according to the assessment of the caregivers
Where this trial is running
Zurich
- University Hospital Zuerich — Zurich, Switzerland (Recruiting)
Study contacts
- Principal investigator: Anna Götz, PhD — Usz
- Study coordinator: Anna Götz, PhD
- Email: anna.goetz@usz.ch
- Phone: +41 43 253
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.